Results 21 to 30 of about 29,030 (239)

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Blood Advances, 2023
Key Points • Biomarker scores are a feasible eligibility criterion for high-risk GVHD in which the prompt initiation of treatment is a priority.• The combination of natalizumab with corticosteroids was not effective in improving outcomes for patients ...
M. A. Al Malki, Kaitlyn London, Janna Baez, Y. Akahoshi, W. Hogan, Aaron M. Etra, H. Choe, E. Hexner, A. Langston, S. Abhyankar, D. Ponce, Zachariah M DeFilipp, C. Kitko, K. Adekola, R. Reshef, F. Ayuk, Alexandra Capellini, C. Chanswangphuwana, M. Eder, Gilbert W Eng, Isha Gandhi, S. Grupp, Sigrun Gleich, E. Holler, N. Javorniczky, Stelios Kasikis, Steven Kowalyk, George Morales, U. Özbek, W. Rösler, Nikolaos Spyrou, R. Young, G. Yanik, Yi-Bin Chen, R. Nakamura, J. Ferrara, J. Levine   +36 more
semanticscholar   +1 more source

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

JAMA Neurology, 2020
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk ...
G. Luna, Peter Alping, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, T. Frisell   +15 more
semanticscholar   +1 more source

Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy

Journal of Neurology Neurosurgery & Psychiatry, 2023
Background After natalizumab discontinuation severe relapses can occur despite pregnancy, but third trimester exposure is associated with neonatal haematological abnormalities (HA). The best time point for stopping natalizumab during pregnancy is unclear.
S. Thiel, Nastassja Litvin, Sabrina Haben, Ralf Gold, Kerstin Hellwig   +4 more
semanticscholar   +1 more source

Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study

Journal of Neurology, 2023
Introduction EASIER is a multicenter, observational, cross-sectional study investigating the consumption of healthcare resources, including healthcare professional (HCP) active working time, the costs associated with the current natalizumab intravenous ...
M. Filippi, Luigi Grimaldi, A. Conte, R. Totaro, Maria Rosaria Valente, S. Malucchi, F. Granella, C. Cordioli, V. Brescia Morra, C. Zanetta, D. Perini, L. Santoni, V. R. A. S. O. A. G. V. M. A. A. R. R. I. L. M. E. R. Ziccone Garba Motta Albanesi Oddo Impagliato Ferra, V. Ziccone, R. Garba, A. Motta, S. Albanesi, O. Oddo, A. Impagliato, G. Ferrazzano, V. Di Rosa, M. Tartaglia, A. Di Vito, A. Galassi, R. Prota, R. Garbo, I. Del Negro, L. Nesi, M. Capobianco, E. Tsantes, R. Agosta, A. M. Valleri, L. Galuppini, S. Mascara, F. Bertocchi, E. Chiarini, M. Moccia, G. Puorro   +37 more
semanticscholar   +1 more source

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy

JAMA Network Open, 2022
Key Points Question Is early natalizumab cessation before or during the first trimester of pregnancy associated with multiple sclerosis relapse occurrence and relapse-related disability?
K. Hellwig, M. Tokic, S. Thiel, Nina Esters, C. Spicher, N. Timmesfeld, A. Ciplea, R. Gold, A. Langer-Gould   +8 more
semanticscholar   +1 more source

Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis

Journal of Neurology Neurosurgery & Psychiatry, 2023
Background Natalizumab is effective in the treatment of multiple sclerosis (MS). In 2021, the European Medicines Agency approved the subcutaneous (SC) variant of natalizumab which can be used instead of intravenous administration.
Alyssa A. Toorop, Z. V. van Kempen, M. Steenhuis, J. Nielsen, L. Sinnige, G. Van Dijk, C. Roosendaal, E. Arnoldus, E. Hoitsma, Birgit I. Lissenberg-Witte, B. D. de Jong, B. W. Oosten, E. Strijbis, B. Uitdehaag, T. Rispens, J. Killestein   +15 more
semanticscholar   +1 more source

Natalizumab

Reactions Weekly, 2012
Hoofnagle JH.
europepmc   +3 more sources

A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. [PDF]

, 2020
Neurologists managing women with Multiple Sclerosis (MS) need information about the safety of disease modifying drugs (DMDs) during pregnancy. However, this knowledge is limited.
A Haghikia, AL Nguyen, C Weber-Schoendorfer, D Moher, E Lu, E Lu, E Portaccio, G Comi, HV De Las, J Thone, JP Higgins, L Shamseer, MK Houtchens, N Ebrahimi, PK Coyle, R Alroughani, R Boskovic, S Herbstritt, S Pernia, S Thiel, SC MacDonald   +20 more
core   +1 more source

Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

PharmacoEconomics - Open, 2023
Introduction A subcutaneous (SC) formulation of natalizumab has been recently authorised for multiple sclerosis patients. This study aimed to assess the implications of the new SC formulation, and to compare the annual treatment costs of SC versus ...
A. M. Alonso Torres, Á. G. Arévalo Bernabé, N. Becerril Ríos, M. F. Hellín Gil, J. M. Martínez Sesmero, V. Meca Lallana, L. Ramió-Torrentá, A. Rodríguez-Antigüedad, L. Gómez Maldonado, I. Triana Junco, M. Gómez-Barrera, N. Espinoza Cámac, I. Oyagüez   +12 more
semanticscholar   +1 more source

Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis

Journal of Central Nervous System Disease, 2023
Background Changes in brain connectivity occur in patients with multiple sclerosis (MS), even in patients under disease-modifying therapies. Using magnetic resonance imaging (MRI) to asses patients treated with disease-modifying therapies, such as ...
Diogo G. Corrêa, Eelco van Duinkerken, João Gabriel D. Farinhas, Valéria C. Pereira, Emerson L. Gasparetto, Soniza V. Alves-Leon, Fernanda Cristina R. Lopes   +6 more
doaj   +1 more source